Case Fatality Among People with Drug-susceptible TB Enrolled in a Private Health Sector TB Treatment Support Program in Bihar, India During the First Year of the COVID-19 Pandemic

Overview

Journal PLOS Glob Public Health

Specialty Public Health

Date 2024 Sep 12

PMID 39264895

Authors

Lena Faust

Ayushi Ranjan

Nita Jha

Madhukar Pai

Sophie Huddart

Affiliations

Soon will be listed here.

Abstract

Experiencing 27% of the global tuberculosis (TB) burden, India's TB epidemic is the largest in the world. Due to COVID-19-related disruptions to TB programs, India has also seen the largest drop in TB case notifications of any country globally. We estimated case fatality among people treated for TB in India during the pandemic and compared these to pre-pandemic estimates. A random sample of 4,000 adults enrolled in World Health Partners (WHP), a private sector TB treatment support program (enrolling only people with drug-susceptible TB) in Bihar, India in the first year of COVID-19 (Mar 2020-Mar 2021) were contacted via phone to collect information on TB case fatality and other relevant covariates. Inverse probability of selection (IPS) weighting was used to obtain selection-bias-corrected in-treatment and post-treatment case fatality estimates. Covariates associated with (but not necessarily causal of) case fatality were identified by estimating adjusted hazard ratios (HRs) using the Cox proportional hazards model. WHP enrolled 19,826 adult drug-susceptible TB patients in the first year of COVID-19 (Mar 2020 to Mar 2021). Of our random sample of 4,000 patients, n = 2,962 (74.1%) answered the follow-up call. Unweighted and IPS-weighted in-treatment case fatality in the primary analysis were 6.12% (95%CI: 5.31-6.97%) and 6.07% (95%CI: 5.22-6.93%), respectively. Post-treatment case fatality estimates were 0.97% (95%CI: 0.61-1.33%) (unweighted) and 1.27% (95%CI: 0.79-1.79) (IPS-weighted). Our IPS-weighted estimates for in-treatment and post-treatment case fatality were similar to pre-pandemic IPS-weighted estimates (in-treatment: 7.27%, 95%CI: 5.97%- 8.49% and 12 months post-treatment: 1.23, 95%CI: 0.75-1.73). Although not higher than pre-pandemic estimates, the observed case fatality in this private sector cohort of people treated for drug-susceptible TB during COVID-19 in Bihar, India is above the level needed to reach the 2025 and 2030 End TB Strategy targets for reductions in TB deaths, underlining the extent of pandemic-related setbacks to TB elimination.

References

Pai M, Kasaeva T, Swaminathan S . Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022; 386(16):1490-1493. DOI: 10.1056/NEJMp2118145. View

Diwan V, Sharma M, Sahoo K, Negi S, Kalyanasundaram M, Tiwari R . The perspectives of community members on COVID-19-related social stigma and mitigation strategies: A qualitative study in Madhya Pradesh, India. J Family Med Prim Care. 2023; 11(11):7406-7411. PMC: 10041312. DOI: 10.4103/jfmpc.jfmpc_526_22. View

Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T . A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021; 5(4):529-538. DOI: 10.1038/s41562-021-01079-8. View

Zimmer A, Shyam Klinton J, Oga-Omenka C, Heitkamp P, Nawina Nyirenda C, Furin J . Tuberculosis in times of COVID-19. J Epidemiol Community Health. 2021; 76(3):310-316. PMC: 8453591. DOI: 10.1136/jech-2021-217529. View

Chesnaye N, Stel V, Tripepi G, Dekker F, Fu E, Zoccali C . An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022; 15(1):14-20. PMC: 8757413. DOI: 10.1093/ckj/sfab158. View

Varshney K, Patel H, Kamal S . Trends in Tuberculosis Mortality Across India: Improvements Despite the COVID-19 Pandemic. Cureus. 2023; 15(4):e38313. PMC: 10226868. DOI: 10.7759/cureus.38313. View

Chatterjee S, Das P, Vassall A . Impact of COVID-19 restrictive measures on income and health service utilization of tuberculosis patients in India. BMC Infect Dis. 2022; 22(1):711. PMC: 9421110. DOI: 10.1186/s12879-022-07681-z. View

Huddart S, Singh M, Jha N, Benedetti A, Pai M . Case fatality and recurrent tuberculosis among patients managed in the private sector: A cohort study in Patna, India. PLoS One. 2021; 16(3):e0249225. PMC: 7996982. DOI: 10.1371/journal.pone.0249225. View

Subbaraman R, Nathavitharana R, Satyanarayana S, Pai M, Thomas B, Chadha V . The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis. PLoS Med. 2016; 13(10):e1002149. PMC: 5079571. DOI: 10.1371/journal.pmed.1002149. View

10.

Romanowski K, Baumann B, Basham C, Khan F, Fox G, Johnston J . Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019; 19(10):1129-1137. DOI: 10.1016/S1473-3099(19)30309-3. View

11.

Wang X, He W, Lei J, Liu G, Huang F, Zhao Y . Impact of COVID-19 Pandemic on Pre-Treatment Delays, Detection, and Clinical Characteristics of Tuberculosis Patients in Ningxia Hui Autonomous Region, China. Front Public Health. 2021; 9:644536. PMC: 8175850. DOI: 10.3389/fpubh.2021.644536. View

12.

Kumar V, Pandi-Perumal S, Trakht I, Thyagarajan S . Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines. 2021; 6(1):60. PMC: 8169891. DOI: 10.1038/s41541-021-00327-2. View

13.

Suissa S . Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007; 16(3):241-9. DOI: 10.1002/pds.1357. View

14.

Mannan S, Oga-Omenka C, Soman ThekkePurakkal A, Huria L, Kalra A, Gandhi R . Adaptations to the first wave of the COVID-19 pandemic by private sector tuberculosis care providers in India. J Clin Tuberc Other Mycobact Dis. 2022; 28:100327. PMC: 9295336. DOI: 10.1016/j.jctube.2022.100327. View

15.

Kwan A, Daniels B, Saria V, Satyanarayana S, Subbaraman R, McDowell A . Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities. PLoS Med. 2018; 15(9):e1002653. PMC: 6155454. DOI: 10.1371/journal.pmed.1002653. View

16.

Bhargava A, Shewade H . The potential impact of the COVID-19 response related lockdown on TB incidence and mortality in India. Indian J Tuberc. 2020; 67(4S):S139-S146. PMC: 7348601. DOI: 10.1016/j.ijtb.2020.07.004. View

17.

Shrinivasan R, Rane S, Pai M . India's syndemic of tuberculosis and COVID-19. BMJ Glob Health. 2020; 5(11). PMC: 7670552. DOI: 10.1136/bmjgh-2020-003979. View

18.

Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott A . The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022; 10(6):603-622. PMC: 8942481. DOI: 10.1016/S2213-2600(22)00092-3. View

19.

Faust L, Zimmer A, Kohli M, Saha S, Boffa J, Bayot M . SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector. Microbes Infect. 2020; 22(10):511-514. PMC: 7553871. DOI: 10.1016/j.micinf.2020.10.005. View

20.

Easton A, Salerno M, Trieu L, Humphrey E, Kaba F, Macaraig M . Cohort study of the mortality among patients in New York City with tuberculosis and COVID-19, March 2020 to June 2022. PLOS Glob Public Health. 2023; 3(4):e0001758. PMC: 10132536. DOI: 10.1371/journal.pgph.0001758. View